A factor to consider is the ongoing treatment of HIV/AIDS patients with cotrimoxazole, a bacterial dhfr/dhps inhibitor used to treat respiratory tract infections and to prevent opportunistic infections. This evidence concerns the gene DHPS and Opportunistic infection.